Beyondspring (NASDAQ:BYSI) released its earnings results on Wednesday. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.07), Fidelity Earnings reports.
Shares of Beyondspring stock opened at $15.30 on Friday. The business has a 50-day moving average price of $13.51 and a 200 day moving average price of $16.93. Beyondspring has a fifty-two week low of $11.26 and a fifty-two week high of $24.80. The firm has a market cap of $375.44 million, a P/E ratio of -6.32 and a beta of 1.21.
BYSI has been the subject of a number of research analyst reports. ValuEngine upgraded shares of Beyondspring from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Zacks Investment Research lowered shares of Beyondspring from a “buy” rating to a “hold” rating in a report on Thursday, October 24th. HC Wainwright reissued a “buy” rating and set a $41.00 price objective on shares of Beyondspring in a report on Wednesday, September 18th. Finally, William Blair began coverage on shares of Beyondspring in a research report on Tuesday, December 3rd. They issued an “outperform” rating for the company. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Beyondspring presently has an average rating of “Buy” and an average price target of $30.00.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
See Also: How to calculate compound interest
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.